Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/sitagliptin - Dong Wha Pharmaceutical

Next Previous
Drug Profile

Dapagliflozin/sitagliptin - Dong Wha Pharmaceutical

Alternative Names: DW6-012

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong Wha Pharmaceutical
  • Class Anti-ischaemics; Antihyperglycaemics; Antineoplastics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Fluorobenzenes; Gene therapies; Glucosides; Heart failure therapies; Hepatoprotectants; Immunotherapies; Ketones; Obesity therapies; Pyrans; Pyrazines; Small molecules; T lymphocyte cell therapies; Triazoles; Urologics
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 26 Mar 2025 Dapagliflozin/sitagliptin is still in phase-I development in Type 2 diabetes mellitus (In volunteers) in South Korea (PO)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea (PO)
  • 28 May 2024 Launched for Type 2 diabetes mellitus in South Korea (PO) (NCT06875193)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top